Quick Answer
Tvardi Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $7.14 million for the year ending 2024.
- Tvardi Therapeutics, Inc. showed a decrease of -66.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2023 to 2024.
- This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2025.
- XBRL data for this metric is available from 2016 to 2024 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2016 to 2024), Tvardi Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 8,198.8%.
- Historical annual values: Fiscal year 2024: $7.14 million | Fiscal year 2023: $20.97 million | Fiscal year 2022: $41.87 million | Fiscal year 2021: $23.03 million | Fiscal year 2020: $135.08 million | Fiscal year 2019: $19.89 million | Fiscal year 2018: $13.47 million | Fiscal year 2017: $911.0 thousand | Fiscal year 2016: $86.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: